| Title: | Genetic risk, metabolic syndrome, and gastrointestinal cancer risk: A prospective cohort study |
| Journal: | Cancer Medicine |
| Published: | 22 Jun 2022 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/35730595/ |
| DOI: | https://doi.org/10.1002/cam4.4923 |
| URL: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844643 |
| Citations: | 6 (4 in last 2 years) as of 8 Aug 2024 |
Publication 12331
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND: Gastrointestinal (GI) cancer risk has been associated with metabolic syndrome (MetS), a surrogate indicator for unhealthy lifestyles, and a number of genetic loci, but the combined effect of MetS and genetic variants on GI cancer risk is uncertain.</p>
METHODS: We included 430,036 participants with available MetS and genotype data from UK Biobank. During the follow-up time, 5494 incident GI cancer cases, including esophageal cancer, gastric cancer, and colorectal cancer, were identified. We created a GI polygenic risk score (GI-PRS) for overall GI cancer derived from three site-specific cancer PRSs. Cox proportional hazards regression was used to estimate the associations of MetS and GI-PRS with the risk of GI cancer.</p>
RESULTS: MetS was significantly associated with 28% increment in GI cancer risk (hazard ratio [HR]MetS vs. non-MetS : 1.28, 95% confidence interval [CI]: 1.21-1.35, p < 0.0001), whereas a high GI-PRS (top quintile) was associated with 2.28-fold increase in risk (HRhigh vs. low : 2.28, 95% CI: 2.09-2.49, p < 0.0001). Compared with participants without MetS and at low genetic risk (bottom quintile of GI-PRS), those with MetS and at high genetic risk had 2.75-fold increase in GI cancer risk (HR: 2.75, 95% CI: 2.43-3.12, p < 0.0001). Additionally, MetS in comparison with no MetS had 1.49‰, 2.75‰, and 3.37‰ absolute risk increases in 5 years among participants at low, intermediate (quintiles 2-4 of GI-PRS) and high genetic risk, respectively, representing the number of subjects diagnosed as MetS causing a new GI cancer case in 5 years were 669, 364, and 296, respectively.</p>
CONCLUSIONS: Metabolic and genetic factors may jointly contribute to GI cancer risk and may serve as predictors by quantitative measurements to identify high-risk populations of GI cancer for precise prevention.</p>
6 Keywords
- Humans
- Metabolic Syndrome
- Proportional Hazards Models
- Prospective Studies
- Risk Factors
- Stomach Neoplasms
7 Authors
- Yaqian Liu
- Caiwang Yan
- Shuangshuang Yin
- Tianpei Wang
- Meng Zhu
- Li Liu
- Guangfu Jin
1 Application
| Application ID | Title |
|---|---|
| 68209 | Associations of metabolic syndrome and pan-cancer risk stratified by polygenic risk score |
Enabling scientific discoveries that improve human health